Drug

Pertussis Vaccine

Approved · EMA

Emerging researchLate-stage development

Also known as Bordetella pertussis, Pertussis Vaccine, Whole Cell (Adsorbed), pertussis, Pertussis vaccines.

RxNorm8080 ChEMBLCHEMBL2109219 ATCJ07AJ52 ATCJ07AJ02UNII2QNL82089R

Research papers

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Approval: VacPertagen (EMA)

Regulatory2026-01-09EMA

Recent increase in infant pertussis cases in Europe and the critical importance of antenatal immunizations: We must do better…now.

Research2024-07-02International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Impact of Pertussis Vaccination in Pregnancy on Maternal Protection Offered to Young Infants

Clinical trial2016-12-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Pertussis Vaccine

Aliases & brands

Bordetella pertussisPertussis Vaccine, Whole Cell (Adsorbed)pertussisPertussis vaccines

RxNorm CUI

8080

ChEMBL ID

CHEMBL2109219

ATC codes

J07AJ52J07AJ02

UNII

2QNL82089R

Regulatory jurisdictions

ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2026-01-09

Latest approval

2026-01-09

Authorities

EMA

Total events

emaEuropean Medicines Agency· 1 event

2026-01-09Approval

Approval: VacPertagen (EMA)

Indication: VacPertagen is indicated for: - booster immunisation against pertussis of individuals 12 years of age and older,- passive protection against pertussis in early infancy… Show full indication

VacPertagen is indicated for: - booster immunisation against pertussis of individuals 12 years of age and older,- passive protection against pertussis in early infancy following maternal immunisation during pregnancy.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

1 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2016

Late-stage (III+)

Completed

PHASE DISTRIBUTIONn = 1

Phase 41

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Impact of Pertussis Vaccination in Pregnancy on Maternal Protection Offered to Young Infants

CompletedPH IVUniversiteit Antwerpenn=992016

Recent completions

Trials that read out recently, adding to the completed evidence base.

Impact of Pertussis Vaccination in Pregnancy on Maternal Protection Offered to Young Infants

CompletedPH IVUniversiteit Antwerpenn=992016

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Recent increase in infant pertussis cases in Europe and the critical importance of antenatal immunizations: We must do better…now.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024 · 35 cites